Journal of magnetic resonance imaging : JMRI
-
J Magn Reson Imaging · Mar 2019
Diffusion Kurtosis at 3.0T as an in vivo Imaging Marker for Breast Cancer Characterization: Correlation With Prognostic Factors.
Diffusion-kurtosis imaging (DKI) has preliminarily shown promise as a relatively new MRI technique to provide useful information regarding breast lesions, but the diagnostic performance of DKI has not been fully evaluated. ⋯ 2 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2019;49:845-856.
-
J Magn Reson Imaging · Mar 2019
Comparative StudyIntrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia.
Current imaging guidelines do not specify the preferred hepatobiliary contrast agent when differentiating hepatocellular adenoma (HCA) from focal nodular hyperplasia (FNH) on MRI. ⋯ 3 Technical Efficacy: Stage 3 J. Magn. Reson. Imaging 2019;49:700-710.
-
J Magn Reson Imaging · Mar 2019
Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic-Based Model vs. PI-RADS v2.
Multiparametric MRI (mp-MRI) combined with machine-aided approaches have shown high accuracy and sensitivity in prostate cancer (PCa) diagnosis. However, radiomics-based analysis has not been thoroughly compared with Prostate Imaging and Reporting and Data System version 2 (PI-RADS v2) scores. ⋯ 3 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2019;49:875-884.
-
J Magn Reson Imaging · Mar 2019
Noninvasive Prediction of IDH1 Mutation and ATRX Expression Loss in Low-Grade Gliomas Using Multiparametric MR Radiomic Features.
Noninvasive detection of isocitrate dehydrogenase 1 mutation (IDH1(+)) and loss of nuclear alpha thalassemia/mental retardation syndrome X-linked expression ((ATRX(-)) are clinically meaningful for molecular stratification of low-grade gliomas (LGGs). ⋯ 3 Technical Efficacy Stage: 2 J. Magn. Reson. Imaging 2019;49:808-817.
-
J Magn Reson Imaging · Mar 2019
A Triple-Classification Radiomics Model for the Differentiation of Primary Chordoma, Giant Cell Tumor, and Metastatic Tumor of Sacrum Based on T2-Weighted and Contrast-Enhanced T1-Weighted MRI.
Preoperative differentiation between primary sacral chordoma (SC), sacral giant cell tumor (SGCT), and sacral metastatic tumor (SMT) is important for treatment decisions. ⋯ 4 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2019;49:752-759.